Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study
BackgroundImmunotherapy has become a powerful clinical strategy for treating recurrent or metastatic cervical cancer (R/M CC). Cadonilimab, a novel anti-PD-1/CTLA-4 bispecific antibody, has shown substantial clinical benefits in cancer treatment. However, there is no real-world evidence of cadonilim...
Saved in:
Main Authors: | Jian Chen, Haijuan Yu, Yingtao Lin, Dan Hu, Li Liu, Renliang Fan, Jianping Zou, Lele Zang, Yao Lin, Rong Lin, Dezhao Chen, Xiaoying Weng, Fenfang Shen, Shaoyu Wang, Wei Zeng, Qihua Tian, Yun Yi, Yuanfeng Chen, Jinjin Miao, Bo Zhang, Yinxia Zou, Fengming Gao, Rong Lian, Lin Yang, Yang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1611696/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01) -
Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01) -
Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01) -
Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01) -
Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
by: Longfeng Zhang, et al.
Published: (2025-07-01)